Skip to Main Content
Skip Nav Destination

In this chapter, a case study of a discovery project to identify potential new clinical agents for treating the cognitive deficits of schizophrenia is presented. Specifically, a hit identification and lead optimization activity is detailed for a novel series of AMPA receptor positive allosteric modulators, which ultimately delivered a clinical development candidate. The challenges of running high-throughput screening to identify positive modulators of ion channels are discussed, along with the opportunity presented by X-ray crystallography to improve the rational basis for onward analogue design. The evolution of the screening cascade, including recombinant and native tissue assays, fluorescent and electrophysiological readouts is outlined, with particular emphasis on the relevance and predictability of in vitro assays to the downstream pharmacodynamic, behavioural and tolerability screens. Additionally, the path to build confidence in the efficacy and safety profile of the clinical candidate is discussed, in light of the generic concerns of tolerability of agents that potentiate excitatory neurotransmission.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal